Spherical amorphous nanoparticles loading with antituberculosis substance rifabutin

Spherical amorphous nanoparticles loading with antituberculosis substance rifabutin

Properties of spherical amorphous nanoparticles loading with antituberculosis substance rifabutin are described. It was shown that rifabutin is loaded completely when content of the substance is 5% from the mass of carrier.

Bibliographic Details
Main Authors:	A. P. Kaplun, N. I. Pakhar’kova, L. A. Poruchikova, D. A. Bezrukov, V. I. Popenko, V. I. Shvets
Format:	Article
Language:	Russian
Published:	MIREA - Russian Technological University 2010-04-01
Series:	Тонкие химические технологии
Subjects:	spherical amorphous nanoparticles triterpenoids birch bark rifabutin
Online Access:	https://www.finechem-mirea.ru/jour/article/view/1002

Similar Items

Spherical Amorphous Nanoparticles from Birch Bark Triterpenoids: Study of the Conditions for the Formation
by: A. N. Bastrich, et al.
Published: (2019-07-01)

Interaction of spherical amorphous nanoparticles of birchbark triterpenoids with bilirubin 77 N.Yu. Rubanyak, E.Yu. Bulychev. Industrial synthesis of 2-aminoethanesulfonic acid (taurine): problems and perspectives
by: L. A. Poruchikova, et al.
Published: (2010-06-01)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
by: Carolina Arana Stanis Schmaltz, et al.
Published: (2019-02-01)

Methods of Betulin Extraction from Birch Bark
by: Olga V. Demets, et al.
Published: (2022-06-01)

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease
by: Thomas Dick, et al.
Published: (2020-02-01)

Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure
by: Jihee Sung, et al.
Published: (2017-02-01)

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections
by: Miranda Monk, et al.
Published: (2022-06-01)

Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
by: Thomas C.S. Martin, et al.
Published: (2020-11-01)

rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis
by: Li MC, et al.
Published: (2022-11-01)

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
by: Wei Jing, et al.
Published: (2017-09-01)

Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex
by: Xiaoqin Le, et al.
Published: (2022-03-01)

Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
by: Sandeep Sharma, et al.
Published: (2017-11-01)

Rifabutin-Induced SIADH and Leucopenia in a Renal Transplant Recipient with Genitourinary Tract Tuberculosis: A Case Report and Review of the Literature
by: Maha Mohamed, et al.
Published: (2022-08-01)

Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations
by: Nadezhda Osipova, et al.
Published: (2023-04-01)

Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan
by: Chia-Jung Kuo, et al.
Published: (2024-01-01)

Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers
by: Chang Min Lee, et al.
Published: (2022-09-01)

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01)

Rifabutin Use in <i>Staphylococcus</i> Biofilm Infections: A Case Series
by: James B. Doub, et al.
Published: (2020-06-01)

Rifabutin for the Treatment of <i>Helicobacter pylori</i> Infection: A Review
by: Javier P. Gisbert
Published: (2020-12-01)

In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex
by: Ka Lip Chew, et al.
Published: (2021-09-01)

Molecular docking analysis and antidiabetic activity of Rifabutin against STZ-NA induced diabetes in albino wistar rats
by: Danish Ahmed, et al.
Published: (2017-09-01)

Nano-Rifabutin entrapment within glucan microparticles enhances protection against intracellular Mycobacterium tuberculosis
by: Tarun K. Upadhyay, et al.
Published: (2019-12-01)

Differential Impact of the rpoB Mutant on Rifampin and Rifabutin Resistance Signatures of Mycobacterium tuberculosis Is Revealed Using a Whole-Genome Sequencing Assay
by: Ming-Chih Yu, et al.
Published: (2022-08-01)

Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study
by: Bahareh Hajikhani, et al.
Published: (2021-09-01)

Rifabutin corneal deposits localized to the deep stroma using anterior segment optical coherence tomography
by: Tianyi Zhang, et al.
Published: (2020-06-01)

Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity
by: Ji Sun Lee, et al.
Published: (2022-07-01)

In Vitro Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae
by: Bosul Lee, et al.
Published: (2021-12-01)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
by: Seni Kouanda, et al.
Published: (2020-06-01)

The use of nanodispersions prepared from birch bark extract for poor soluble substances solubilization.
by: V. V. Krasil’nikova, et al.
Published: (2008-10-01)

Correlation of rpoB mutations with minimal inhibitory concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa
by: Ivy - Rukasha, et al.
Published: (2016-12-01)

Characterization of Self-Growing Biomaterials Made of Fungal Mycelium and Various Lignocellulose-Containing Ingredients
by: Ilze Irbe, et al.
Published: (2022-10-01)

Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn’s Disease
by: Helena Rouco, et al.
Published: (2020-10-01)

Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of <i>Helicobacter pylori</i>: Randomized ERADICATE Hp Trial
by: Ira N. Kalfus, et al.
Published: (2020-10-01)

Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
by: Olga P. Nyssen, et al.
Published: (2022-03-01)

Utilization of Suberinic Acids Containing Residue as an Adhesive for Particle Boards
by: Raimonds Makars, et al.
Published: (2022-06-01)

The interaction of water with archaeological and ethnographic birch bark and its effects on swelling, shrinkage and deformations
by: Johanna Klügl, et al.
Published: (2021-01-01)

Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin
by: Alison J. Beech, et al.
Published: (2023-08-01)

Triterpene Compound from Ethyl Acetate Fraction of Kesambi Bark (Schleichera oleosa) and Its Activity as Anti-Bacterial
by: Weny J.A. Musa, et al.
Published: (2024-01-01)

Electrospun Bioactive Wound Dressing Containing Colloidal Dispersions of Birch Bark Dry Extract
by: Francis Kamau Mwiiri, et al.
Published: (2020-08-01)

Analytical Method Cluster Development for Comprehensive Characterisation of Suberinic Acids Derived from Birch Outer Bark
by: Daniela Godina, et al.
Published: (2023-02-01)